|Bid||0.0830 x 7867300|
|Ask||0.0850 x 1875100|
|Day's range||0.0830 - 0.0830|
|52-week range||0.0670 - 0.1950|
|Beta (5Y monthly)||0.24|
|PE ratio (TTM)||N/A|
|Earnings date||17 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||19 Oct 2012|
|1y target est||N/A|
I am pleased to provide you with a detailed update on BTC Health Limited's (ASX:BTC) investments, along with an operational update of BTC's wholly owned investee companies.
The primary objective for BTC Speciality Health is to increase market share through organic growth. New products will continue to be sourced by BioImpact and will enable BTC Speciality Health to expand its product range within pain management and critical care.
BTC Health Limited (ASX:BTC) is pleased to announce its investee company, BioImpact Pty Ltd, has acquired exclusive distribution rights for specialty respiratory brands Bronchitol(R) and Aridol(R) from Pharmaxis (ASX:PXS) in Australia, New Zealand, Singapore, Malaysia, Hong Kong and South Korea (Bronchitol(R) only).